EcoDrugPlus

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSCAFG00020015508
Gene Symbol: LYN
3 Cross references
197 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSCAFG00020020119
Gene Symbol: MALT1
3 Cross references
197 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSCAFG00020012432
Gene Symbol: MAPKAPK2
3 Cross references
240 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSCAFG00020017054
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSCAFG00020014775
Gene Symbol: MKNK1
3 Cross references
168 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSCAFG00020017316
Gene Symbol: MKNK2
3 Cross references
221 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSCAFG00020019541
Gene Symbol: MCL1
3 Cross references
245 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSCAFG00020017002
Gene Symbol: MDM2
3 Cross references
257 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSCAFG00020007371
Gene Symbol: MET
3 Cross references
206 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSCAFG00020017633
Gene Symbol: MPL
3 Cross references
186 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSCAFG00020026180
Gene Symbol: MLST8
3 Cross references
202 Possible Orthologues:

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSCAFG00020020291
Gene Symbol: NQO1
3 Cross references
195 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).